SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Girerd N)
 

Search: WFRF:(Girerd N) > Diuretic therapy as...

Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction

Coiro, S. (author)
Girerd, N. (author)
McMurray, J. J. V. (author)
show more...
Pitt, B. (author)
Swedberg, Karl, 1944 (author)
Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
van Veldhuisen, D. J. (author)
Lamiral, Z. (author)
Rossignol, P. (author)
Zannad, F. (author)
show less...
 (creator_code:org_t)
2021-05-06
2021
English.
In: Clinical Research in Cardiology. - : Springer Science and Business Media LLC. - 1861-0684 .- 1861-0692. ; 110, s. 1308-1320
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background Loop diuretics are the mainstay of congestion treatment in patients with heart failure (HF). We assessed the association between baseline loop diuretic use and outcome. We also compared the increment in risk related to diuretic dose with conventional prognostic enrichment criteria used in the EMPHASIS-HF trial, which included patients with systolic HF and mild symptoms, such as prior hospitalization and elevated natriuretic peptides. Methods Individual analyses were performed according to baseline loop diuretic usage (furosemide-equivalent dose > 40 mg, 1-40 mg, and no furosemide), and according to enrichment criteria adopted in the trial [i.e. recent hospitalization (< 30 days or 30 to 180 days prior to randomization) due to HF or other cardiovascular cause, or elevated natriuretic peptides]. The primary endpoint was a composite of cardiovascular death or HF hospitalization. Results Loop diuretic usage at baseline (HR for > 40 mg furosemide-equivalent dose = 3.16, 95% CI 2.43-4.11; HR for 1-40 mg = 2.06, 95% CI 1.60-2.65) was significantly associated with a higher risk for the primary endpoint in a stepwise manner when compared to no baseline loop diuretic usage. In contrast, the differences in outcome rates were more modest when using history of hospitalization and/or BNP: all HR ranged from 1 (reference, non-HF related CV hospitalization > 30 days) to 2.04 (HF hospitalization < 30 days). The effect of eplerenone on the primary endpoint was consistent across subgroups in both analyses (P for interaction >= 0.2 for all). Conclusions Loop diuretic usage (especially at doses > 40 mg) identified patients at higher risk than history of HF hospitalization and/or high BNP blood concentrations. Graphic abstract

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Keyword

Heart failure with reduced ejection faction
Eplerenone
Loop diuretics
Heart failure hospitalization
Prognostic enrichment criteria
brain natriuretic peptide
loop diuretics
hospitalization
mortality
survival
eplerenone
Cardiovascular System & Cardiology

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view